Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$12.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 789.68% year-over-year to -$12.1 million; the TTM figure through Mar 2026 stood at $18.3 million (up 71.52% YoY), while the FY2025 annual figure was $29.0 million, up 117.64% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$12.1 million, down from $11.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $12.5 million in Q2 2025, with the low at -$12.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $4.1 million (2022), against an average of $3.2 million.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 866.13% in 2025, then sank 789.68% in 2026.
• Crinetics Pharmaceuticals' Change in Accured Expenses stood at $4.1 million in 2022, then plunged by 53.47% to $1.9 million in 2023, then soared by 221.89% to $6.1 million in 2024, then surged by 82.73% to $11.2 million in 2025, then plunged by 207.95% to -$12.1 million in 2026.
• Business Quant data shows CRNX's Change in Accured Expenses at -$12.1 million in Q1 2026, $11.2 million in Q4 2025, and $6.6 million in Q3 2025.